Alex Sevanian
Overview
Explore the profile of Alex Sevanian including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
981
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bae S, Wu G, Sevanian A, Schultz B, Zamir E, Rao N
Korean J Ophthalmol
. 2007 Apr;
21(1):21-7.
PMID: 17460428
Purpose: Demonstrate unequivocally the generation of nitric oxide in experimental autoimmune uveoretinitis by electron spin resonance spectroscopy (ESR) using ferrous iron complex of N-methyl-D-glucamine dithiocarbamate, (MGD)(2)-Fe(2+), as a spin trap....
2.
Oliveira J, Sevanian A, Rodrigues R, Apolinario E, Abdalla D
Clin Biochem
. 2006 Jun;
39(7):708-14.
PMID: 16782081
Objectives: To determine the minimally modified electronegative LDL (LDL-) and its autoantibodies in coronary syndromes. Design And Methods: LDL(-) and its autoantibodies were determined by ELISA in patients with acute...
3.
Siems W, Quast S, Peter D, Augustin W, Carluccio F, Grune T, et al.
Kidney Blood Press Res
. 2006 Mar;
28(5-6):302-6.
PMID: 16534225
Background/aims: Oxidative stress occurs in chronic renal failure patients undergoing hemodialysis (HD). The objective of our study was to measure oxidation products of cholesterols, so-called oxysterols, in the serum of...
4.
Hwang J, Hodis H, Hsiai T, Asatryan L, Sevanian A
Atherosclerosis
. 2006 Jan;
189(1):76-82.
PMID: 16386257
Annexin II (ANXII) is a receptor for tissue plasminogen activator and plasminogen for the conversion to plasmin, which, in turn, induces metalloproteinase-9 (MMP-9). 17beta-Estradiol (E(2)) is reported to decrease plasminogen...
5.
Gago-Dominguez M, Castelao J, Pike M, Sevanian A, Haile R
Cancer Epidemiol Biomarkers Prev
. 2005 Dec;
14(12):2829-39.
PMID: 16364997
We have recently proposed a common mechanistic pathway by which obesity and hypertension lead to increased renal cell cancer risk. Our hypothesis posits lipid peroxidation, which is a principal mechanism...
6.
Damasceno N, Sevanian A, Apolinario E, Oliveira J, Fernandes I, Abdalla D
Clin Biochem
. 2005 Nov;
39(1):28-38.
PMID: 16310760
Objectives: To produce a monoclonal antibody (MAb) against electronegative LDL (LDL-) for detecting this modified lipoprotein in blood plasma and tissues. Design And Methods: LDL- was isolated from human blood...
7.
Rouhanizadeh M, Hwang J, Clempus R, Marcu L, Lassegue B, Sevanian A, et al.
Free Radic Biol Med
. 2005 Nov;
39(11):1512-22.
PMID: 16274886
Modified low-density lipoprotein (LDL) induces reactive oxygen species (ROS) production by vascular cells. It is unknown if specific oxidized components in these LDL particles such as oxidized-1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine (ox-PAPC) can stimulate...
8.
Leonarduzzi G, Gamba P, Sottero B, Kadl A, Robbesyn F, Calogero R, et al.
Free Radic Biol Med
. 2005 Oct;
39(9):1152-61.
PMID: 16214031
To investigate the proinflammatory potential of cholesterol and cholesterol oxidation products (oxysterols), which are present in oxidized low-density lipoproteins, foam cells, and fibrotic plaque, we used an in vitro model...
9.
Oxidized phospholipids mediate occludin expression and phosphorylation in vascular endothelial cells
DeMaio L, Rouhanizadeh M, Reddy S, Sevanian A, Hwang J, Hsiai T
Am J Physiol Heart Circ Physiol
. 2005 Sep;
290(2):H674-83.
PMID: 16172163
Oxidized l-alpha-1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine (OxPAPC), a component of minimally modified LDL, induces production of proinflammatory cytokines and development of atherosclerotic lesions. We tested the hypothesis that OxPAPC alters expression, phosphorylation, and localization...
10.
Hwang J, Mack W, Xiang M, Sevanian A, Lobo R, Hodis H
Atherosclerosis
. 2005 Jul;
181(2):375-80.
PMID: 16039293
The estrogen in the prevention of atherosclerosis trial (EPAT) was a 2-year randomized controlled trial in which unopposed 17beta-estradiol reduced subclinical atherosclerosis progression, measured as change in carotid intima-media thickness...